-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure highlights peer-reviewed study showing cryoablation advantages over radiofrequency ablation in early-stage breast cancer

PUBT·06/23/2026 12:15:38
Listen to the news
IceCure highlights peer-reviewed study showing cryoablation advantages over radiofrequency ablation in early-stage breast cancer
  • IceCure highlighted a newly published peer-reviewed review in the International Journal of Surgery backing cryoablation for early-stage breast cancer.
  • The article reported favorable clinical outcomes for ProSense cryoablation versus radiofrequency ablation, citing procedural control and anesthesia advantages without compromising safety.
  • Prior results were already presented at the 2025 Japanese Breast Cancer Society meeting; the company plans to attend the 2026 meeting on June 25-27.
  • Terumo is expected to file a Japan breast-cancer regulatory submission for ProSense in the second half of 2026, using international data and Japanese clinical experience.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on June 23, 2026, and is solely responsible for the information contained therein.